Naveglitazar is a dual PPARα/γ agonist with γ-dominant activity, exhibiting glucose-lowering potential in animal models; it functions as a potent and efficacious insulin sensitizer in rodents, with a novel profile that may lead to an improved therapeutic agent for the treatment of type 2 diabetes and associated dyslipidemia.